PROMAZINE—IPRONIAZID: A BRIEF REPORT
Abstract
The effects of Marsilid cannot be assessed separately and objectively in a few cases also receiving other therapy, but improvement in the majority was unexpectedly rapid and greater than that shown on a previous regimen. Marsilid dosage was begun at a lower level than that given by Smarr, Wolf and Pressman(1) whilst the response to corticosteriod therapy in case no. 5 was similar to that reported by Trethowan and Shand(2,3) in chlorpromazine–jaundice.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
